Clinical trials: Genome
Healthy Adult
Data-driven Rural Interventions for Vitality and Endurance Pilot Study
The study aims to explore whether data driven, personalized wellness interventions-based on integrated genomic, clinical, behavioral, and functional data- are feasible in a rural facing setting and can produce measurable…
- Trial name
- DRIVE (NCT07872995)
- Testing
- Data-driven lifestyle coaching
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- McLaughlin Research Institute for Biomedical Sciences, Inc.
Non-small Cell Lung Cancer
Deciphering Antitumour Response and Resistance With INtratumour Heterogeneity
DARWIN II is a multi-arm non-randomised phase II trial, Eligible patient will be those who relapse with NSCLC (clinical trials.gov ref. NCT02183883). .
- Trial name
- DARWINII (NCT02314481)
- Testing
- MPDL3280A, Vemurafenib, Alectinib
- Where
- United Kingdom
- Volunteers
- 50 people
- Sponsor
- University College, London
Whole Genome Sequencing, Acute Myeloid Leukemia
Whole Genome Sequencing (ChromoSeq) as an Adjunct to Conventional Genomic Profiling in AML and MDS
This is a single institution, prospective study of the whole genome sequencing assay, ChromoSeq. Using prospectively collected patient data, coupled with physician surveys, the investigators seek to determine the feasibility of…
- Conditions
- Whole Genome Sequencing, Acute Myeloid Leukemia, Myelodysplastic Syndromes
- Trial name
- NCT04986657
- Testing
- ChromoSeq
- Where
- United States
- Volunteers
- 325 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Waldenstrom's Macroglobulinemia
Study of Ibrutinib in Patients With Symptomatic, Previously Untreated Waldenstrom's Macroglobulinemia, and Impact on Tumor Genomic Evolution Using Whole Genome Sequencing
This research study is studying a drug called ibrutinib as a possible treatment for untreated Waldenstrom's Macroglobulinemia (WM).
- Trial name
- NCT02604511
- Testing
- Ibrutinib
- Where
- 2 sites in United States
- Volunteers
- 31 people
- Sponsor
- Dana-Farber Cancer Institute
Advanced Triple Negative Breast Cancer, Breast Cancer Metastatic
First-Line Sacituzumab Govitecan in Advanced Untreated Triple-Negative Breast Cancer Patients.
The goal of this clinical trial is to learn if the drug Sacituzumab govitecan (SG) reduces disease progression when used as a first-line treatment in adults with advanced triple-negative breast cancer (TNBC) who have not received…
- Conditions
- Advanced Triple Negative Breast Cancer, Breast Cancer Metastatic, Breast Cancer
- Trial name
- NCT07299409
- Testing
- Sacituzumab Govitecan (SG)
- Where
- Canada
- Volunteers
- 24 people
- Sponsor
- Nathalie Levasseur
Haematological Malignancy, Malignant Neoplasm
DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.
This clinical trial is looking at two drugs called dabrafenib and trametinib. Dabrafenib and trametinib are approved as standard of care treatment for adult patients with melanoma (a type of skin cancer) or lung cancer and in…
- Conditions
- Haematological Malignancy, Malignant Neoplasm, Lymphoproliferative Disorders, Neoplasms by Histologic Type
- Trial name
- DETERMINE (NCT07440290)
- Testing
- Dabrafenib, Trametinib
- Where
- 27 sites in United Kingdom
- Volunteers
- 30 people
- Sponsor
- Cancer Research UK
Advanced Solid Tumors, Breast Cancer Recurrent
First-in-Human Study of ATX-559, an Oral Inhibitor of DHX9, in Patients With Advanced or Metastatic Solid Tumors, and Molecularly Defined Cancers
The goal of this study is to identify a safe and tolerated dose of the orally administered DHX9 inhibitor ATX-559. In addition, this study will evaluate the pharmacokinetics, pharmacodynamics and preliminary antitumor activity of…
- Conditions
- Advanced Solid Tumors, Breast Cancer Recurrent, Colorectal Cancer Metastatic, Colon Cancer
- Trial name
- NCT06625515
- Testing
- ATX-559
- Where
- 5 sites in United States
- Volunteers
- 17 people
- Sponsor
- Accent Therapeutics
Hypertrophic Cardiomyopathy, Hypertrophic Obstructive Cardiomyopathy
Hypertrophic Cardiomyopathy Registry, Biobank and Imaging Data Repository
The Hearts in Rhythm Organization (HiRO) is a national network of Canadian researchers/clinicians, working towards a better understanding of the rare genetic causes of sudden cardiac death (SCD).
- Conditions
- Hypertrophic Cardiomyopathy, Hypertrophic Obstructive Cardiomyopathy, Familial Hypertrophic Cardiomyopathy, Cardiomyopathies
- Trial name
- HiRO-HCM (NCT05100420)
- Where
- 17 sites in Canada
- Volunteers
- 2,000 people
- Sponsor
- Montreal Heart Institute
Genetic Diseases
Rady Children's Institute Genomic Biorepository
Rady Children's Institute for Genomic Medicine (RCI) will collect biological samples (such as blood), derived genomic sequences (from DNA and RNA), and clinical features in a Biorepository as a standardized resource for future…
- Trial name
- NCT02917460
- Testing
- Genomic sequencing and molecular diagnostic results, if any
- Where
- United States
- Volunteers
- 102,000 people, healthy volunteers welcome
- Sponsor
- Rady Pediatric Genomics & Systems Medicine Institute
Head and Neck Cancer
Profiles of Expression in HPV+ Versus HPV Head and Neck Cancers
Squamous cell cancers of the head and neck are classically correlated to excessive consumption of alcohol and tobacco and have a rather poor prognosis.
- Trial name
- HPVNGS (NCT06133790)
- Testing
- PCR - Immunohistochemistry - Immunolabelling
- Where
- France
- Sponsor
- GCS Ramsay Santé pour l'Enseignement et la Recherche
Breast Cancer
Comparative Genomic and Genetic Analysis of Paired Primary Breast - Metastatic Tumor Specimens Using High-throughput Platforms
Adequate quality and quantity of RNA may be extracted from paraffin-embedded tumor blocks for gene expression analysis. This has clinical relevance as gene expression signatures may then be profiled using archival tumor blocks…
- Trial name
- NCT01227733
- Testing
- Breast Tumor Blocks
- Where
- Singapore
- Sponsor
- National University Hospital, Singapore
Syphilis
Global Syphilis Sequencing
Syphilis is an important sexually transmitted infection. There has been an epidemic of syphilis amongst men who have sex with men in the United Kingdom in the last decade.
- Trial name
- NCT03709862
- Testing
- Whole Genome Sequencing
- Where
- 5 sites in United Kingdom
- Volunteers
- 726 people
- Sponsor
- London School of Hygiene and Tropical Medicine
Eczema Herpeticum
Etiology of Eczema Herpeticum (EH)
Atopic dermatitis, also called eczema, is a disease with dry, scaly, itchy skin. Those with atopic dermatitis may have complications from skin infections such as eczema herpeticum after herpes simplex virus (HSV) infection.
- Trial name
- NCT03038932
- Where
- United States
- Volunteers
- 69 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Breast Cancer
Study of Radiation Exposure and Bilateral Breast Cancer
This study is being done to find out what factors may be related to the risk of getting a second breast cancer among women who already have breast cancer in one breast.
- Trial name
- NCT00903591
- Testing
- questionaire, blood or saliva sample
- Where
- 6 sites in United States, Canada and 1 more
- Volunteers
- 1,699 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Colorectal Cancer, Breast Cancer
Feasibility Study of Genomic Profiling Methods and Timing in Tumor Samples
This is a feasibility study to look for genetic alterations in tissue and blood samples that may be useful in determining what treatments may be useful in the patient's cancer care.
- Conditions
- Colorectal Cancer, Breast Cancer, Gynecological Cancer, Metastatic
- Trial name
- NCT01703585
- Where
- Canada
- Volunteers
- 45 people
- Sponsor
- University Health Network, Toronto
Breast Cancer Invasive Nos
A Combined GWAS and miRNA for the Identification of Bevacizumab Response Predictors in Metastatic Breast Cancer
GEI-BEV-2011-01 is an Observational multicenter study. The study, involving 200 (100 non-responders and 100 best responders) metastatic breast cancer patients, will search for specific genetic variants (SNPs) and miRNA signatures…
- Trial name
- NCT01598285
- Where
- Spain
- Volunteers
- 26 people
- Sponsor
- Spanish Breast Cancer Research Group
Central Nervous System Neoplasms, Pediatric Cancer
Pediatric Prospective Personalized Immune and Target Identification Trial
PPROSPERITIT is a prospective clinical study assessing the use of comprehensive molecular profiling to define the best matching targeted and immune treatment for relapsed, refractory or very high risk pediatric CNS tumors.
- Conditions
- Central Nervous System Neoplasms, Pediatric Cancer, GEN1 Gene Mutation, Tumor, Brain
- Trial name
- PPROSPERITIT (NCT04859543)
- Testing
- FoundationOneHeme
- Where
- 3 sites in Austria, Czechia
- Volunteers
- 80 people
- Sponsor
- Masaryk University
Breast Cancer Female
GENe EXpression After Regional or General ANesthesia in Patients Undergoing Breast Cancer Surgery
Breast cancer is the most commonly diagnosed cancer in females and the second leading cause of death from cancer in women. It was estimated that 2 million new cases have occurred in 2018 worldwide 1.
- Trial name
- GENEXAN (NCT03779685)
- Testing
- General anesthesia, Regional anesthesia
- Volunteers
- 100 people
- Sponsor
- Azienda Ospedaliera San Gerardo di Monza
Cancer, NGS
Performance Indicators and Impact on the Care Pathway of Sequencing on the SeqOIA and AURAGEN (Seqogen) Platforms for Oncology Patients
As part of the French Genomic Medicine Plan 2025 (FGM), the SeqOIA and AURAGEN platforms were selected to perform high-throughput genomic sequencing.
- Conditions
- Cancer, NGS, Tumor, RARE DISEASE
- Trial name
- SONCO (NCT07147465)
- Where
- 3 sites in France
- Volunteers
- 3,149 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Advanced Solid Tumors, Colorectal Cancer
A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid Tumors
This is a first-in-human, Phase I, open-label, multicenter, dose-escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of VVD-133214…
- Trial name
- NCT06004245
- Testing
- VVD-133214, Pembrolizumab, Bevacizumab
- Where
- 55 sites in United States, Australia and 9 more
- Volunteers
- 280 people
- Sponsor
- Vividion Therapeutics, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.